Loading
Latest filing published 31 Jul 2026 for 艾迪药业, €128k. Read the official filing
Based on 10 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
傅和亮, listed as board member, appears in our data through filings on 艾迪药业 shares, published by SSE / SZSE (CSRC). The record holds 12 filings, for trades running from 25 May 2022 to 31 July 2026.
Every open-market trade on record is a purchase: 12 purchases worth €2.4M, and no sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. So far in 2026, the count stands at 6 purchases and no sales.
In size, the median ticket on the buying side is €158k. Across 12 purchases, this insider has always bought alone, with no colleague buying within 30 days. After 10 purchases with a full 90-day history, the hit rate stands at 50% and the median 90-day move at -1.8%. These figures describe past trades and do not predict future prices.
The newest entry dates from 31 July 2026: an open-market purchase of €128k, in 艾迪药业. Half of the filings or more reach the SSE / SZSE (CSRC) feed on the day of the trade. Until a filing is published, the market cannot know about the trade. These figures are compiled from regulatory filings published by SSE / SZSE (CSRC). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
12 of 12 declarations